GLOCER THOMAS H 4

What Happened Thomas H. Glocer, a director of Merck & Co., Inc. (MRK), received a grant of 405.271 phantom stock units on 2026-03-31. The units are valued at $120.29 each, for a total grant value of $48,750. This was an award/derivative grant (code A), not an open‑market purchase or sale.

Key Details

• Transaction date and price: 2026-03-31 at $120.29 per unit; total value $48,750.
• Instrument/type: 405.271 phantom stock units (derivative award; code A).
• Settlement: Footnote F2 — units are to be settled 100% in cash upon the reporting person’s termination of service, per the elected distribution schedule under the Plan for Deferred Payment of Directors' Compensation.
• Conversion/valuation note: Footnote F1 indicates a 1-for-1 relationship (each unit corresponds to one share for valuation).
• Holdings mention: Footnote F3 notes reported holdings include shares from dividend reinvestment transactions.
• Shares/units owned after transaction: Not specified in the excerpt of the filing provided.
• Timeliness: Filing dated 2026-04-01 for a 2026-03-31 transaction — no late filing flag indicated.

Context Phantom stock units are a form of deferred, cash‑settled compensation tied to the company’s share price; they do not represent immediate ownership of registered common stock. Grants to company directors as part of routine compensation are common and do not necessarily signal an insider view to buy or sell stock.